MGH Institute of Health Professions — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Dalfampridine 10 MG [Ampyra]The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine? * Is the combined treatment associated with better outcomes than the medication (dalfampridine) on its own? * How do the individual treatments (dalfampridine, physical therapy) alone compare to each other? Participants with MS-related mobility deficits will: * Receive 6 weeks of dalfampridine treatment to assess the effects of this treatment. * After stopping the medication for 2 weeks, the investigators will re-evaluate walking, then randomly assign individuals to a 6-week physical therapy program. * Half of the participants will receive physical therapy while resuming dalfampridine treatment. The other half of the participants will receive physical therapy without resuming the medication. Researchers will compare the combination treatment group (medication plus physical therapy) to the physical therapy only group to see if the combined treatment improves walking-related function. Approximately 3 months after finishing the physical therapy program, participants will undergo a final evaluation to see if the treatment effects have been maintained.	SEP	Phase 3	À vérifier	United States	À vérifier
Vagus Nerve StimulatorPaired Vagus Nerve Stimulation (VNS) has been shown to enhance upper extremity motor recovery after ischemic stroke. Prior studies have focused primarily on long-term clinical outcomes, leaving the short-term physiologic response to the intervention poorly understood. The purpose of this study is to examine real-time responses to Vagus Nerve Stimulation (VNS) in individuals with chronic motor impairments after ischemic stroke to better inform Paired VNS dosing. We plan to enroll 50 participants into a single-arm study and perform neurophysiologic assessments during VNS to identify objective markers of stimulation response and examine dose-response relationships.	Accident vasculaire cérébral	Non applicable	À vérifier	United States	À vérifier
Dalfampridine 10 MG [Ampyra]The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine? * Is the combined treatment associated with better outcomes than the medication (dalfampridine) on its own? * How do the individual treatments (dalfampridine, physical therapy) alone compare to each other? Participants with MS-related mobility deficits will: * Receive 6 weeks of dalfampridine treatment to assess the effects of this treatment. * After stopping the medication for 2 weeks, the investigators will re-evaluate walking, then randomly assign individuals to a 6-week physical therapy program. * Half of the participants will receive physical therapy while resuming dalfampridine treatment. The other half of the participants will receive physical therapy without resuming the medication. Researchers will compare the combination treatment group (medication plus physical therapy) to the physical therapy only group to see if the combined treatment improves walking-related function. Approximately 3 months after finishing the physical therapy program, participants will undergo a final evaluation to see if the treatment effects have been maintained.	SEP	Phase 3	À vérifier	United States	À vérifier
Vagus Nerve StimulatorPaired Vagus Nerve Stimulation (VNS) has been shown to enhance upper extremity motor recovery after ischemic stroke. Prior studies have focused primarily on long-term clinical outcomes, leaving the short-term physiologic response to the intervention poorly understood. The purpose of this study is to examine real-time responses to Vagus Nerve Stimulation (VNS) in individuals with chronic motor impairments after ischemic stroke to better inform Paired VNS dosing. We plan to enroll 50 participants into a single-arm study and perform neurophysiologic assessments during VNS to identify objective markers of stimulation response and examine dose-response relationships.	Accident vasculaire cérébral	Non applicable	À vérifier	United States	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
Vagus Nerve Stimulator	Accident vasculaire cérébral	Non applicable	NCT07922200	Biomarkers of Paired VNS	RECRUITING
Dalfampridine 10 MG [Ampyra]	SEP	Phase 3	NCT06136728	AmpPT — Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.